11646

協賛企業

Family history and perceptions about risk and prevention for chronic diseases in primary care: a report from the Family HealthwareTM Impact Trial.

著者 Acheson LS , Wang C , Zyzanski SJ , Lynn A , Ruffin MT , Gramling R , Rubinstein WS , Oʼneill SM , Nease DE ,
Genet Med.2010 Mar 3 ; ():.
この記事をPubMed上で見るPubMedで表示

From the 1Department of Family Medicine, Case Western Reserve University, Cleveland, Ohio; 2Family Medicine Research Division and Department of Reproductive Biology, University Hospitals Case Medical Center, Cleveland, Ohio; 3Program in Cancer Prevention

(14view , 0users)
PURPOSE:: To determine whether family medical history as a risk factor for six common diseases is related to patients' perceptions of risk, worry, and control over getting these diseases. METHODS:: We used data from the cluster-randomized, controlled Family Healthware Impact Trial (FHITr). At baseline, healthy primary care patients reported their perceptions about coronary heart disease, stroke, diabetes, and breast, ovarian, and colon cancers. Immediately afterward, intervention group participants used Family Healthware to record family medical history; this web-based tool stratified familial disease risks. Multivariate and multilevel regression analyses measured the association between familial risk and patient perceptions for each disease, controlling for personal health and demographics. RESULTS:: For the 2330 participants who used Family Healthware immediately after providing baseline data, perceived risk and worry for each disease were strongly associated with family history risk, adjusting for personal risk factors. The magnitude of the effect of family history on perceived risk ranged from 0.35 standard deviation for ovarian cancer to 1.12 standard deviations for colon cancer. Family history was not related to perceived control over developing diseases. Risk perceptions seemed optimistically biased, with 48-79% of participants with increased familial risk for diseases reporting that they were at average risk or below. CONCLUSIONS:: Participants' ratings of their risk for developing common diseases, before feedback on familial risk, parallels but is often lower than their calculated risk based on family history. Having a family history of a disease increases its salience and does not change one's perceived ability to prevent the disease.
PMID: 20216073 [PubMed - as supplied by publisher]
保存論文に追加 保存論文に追加

論文ランキング

週間人気論文ランキング - 閲覧数 (2010/07/24/ 09時更新)

Effects of bacterial toxins on endothelial tight junction in vitro: a mechanism-based investigation.

先週: 1位 ranksame 245view,2users 保存 要約を見る 要約

Prognostic impact of metastatic lymph node ratio on gastric cancer after curative distal gastrectomy.

先週: 3位 rankup 182view,0users 保存 要約を見る 要約

Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients.

先週: 8位 rankup 78view,11users 保存 要約を見る 要約

Personality disorders and biosocial trait theories: The argument for radical legal reform.

先週: 2位 rankdown 76view,2users 保存 要約を見る 要約

The differentiation of rat adipose-derived stem cells into OEC-like cells on collagen scaffolds by co-culturing with OECs.

先週: 9位 rankup 68view,11users 保存 要約を見る 要約

Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).

先週: 5位 rankdown 68view,0users 保存 要約を見る 要約

Integration of the NF-kappaB and mitogen-activated protein kinase/AP-1 pathways at the collagenase-1 promoter: divergence of IL-1 and TNF-dependent signal transduction in rabbit primary synovial fibroblasts.

先週: 7位 ranksame 64view,1users 保存 要約を見る 要約

A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study.

先週: 10位 rankup 34view,28users 保存 要約を見る 要約

Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.

先週: 6位 rankdown 34view,0users 保存 要約を見る 要約

An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).

先週: 4位 rankdown 30view,0users 保存 要約を見る 要約
※view数:週間 user数:合計